A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
367
GSK Investigational Site
Peoria, Arizona, United States
Change in the Montgomery-Asberg Depression Rating Scale (MADRS) after 8 weeks of treatment
Time frame: 8 Weeks
Change in the MADRS score at other timepoints; change in Clinical Global Impression; percentage of remitters and responders based on the MADRS; change in disability, motivation, energy, fatigue and pain;incidence of adverse events over course of study;
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Garden Grove, California, United States
GSK Investigational Site
Irvine, California, United States
GSK Investigational Site
National City, California, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Springfield, Illinois, United States
GSK Investigational Site
Terre Haute, Indiana, United States
GSK Investigational Site
Florence, Kentucky, United States
...and 11 more locations